India, Nov. 16 -- The European Commission (EC) has granted marketing authorization to RASONQUE, the pioneering RAS-targeted medication for pancreatic cancer developed and marketed by Revolution Medicines Inc. (RVMD).

This follows the positive opinion previously issued by the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on RASONQUE and its use in patients with pancreatic ductal adenocarcinoma. The drug was granted an expedited review under the EMA Cancer Medicines Pathfinder project.

Pancreatic ductal adenocarcinoma (PDAC) is the most common and lethal form of pancreatic cancer due to its generally late diagnoses in patients, aggressive nature, and limited response to conventional therapies.

Appro...